This meta-analysis was conducted to analyze the effect of NQO1 polymorphism on the warfarin maintenance dosage. Using strict inclusion and exclusion criteria, we searched PubMed, EMBASE, and the Cochrane Library for eligible studies published prior to July 7, 2021. The required data were extracted, and experts were consulted when necessary. Review Manager Version 5.4 software was used to analyze the relationship between NQO1 polymorphisms and the warfarin maintenance dosage. Four articles involving 757 patients were included in the meta-analysis. Patients who were NQO1 rs10517 G carriers (AG carriers or GG carriers) required a 48% higher warfarin maintenance dose than those who were AA carriers. Patients with NQO1 rs1800566 CT carriers required a 13% higher warfarin dose than those who were CC carriers, with no associations observed with the other comparisons of the NQO1 rs1800566 genotypes. However, the results obtained by comparing the NQO1 rs1800566 genotypes require confirmation, as significant changes in the results were found in sensitivity analyses. Our meta-analysis suggests that the NQO1 rs10517and NQO1 rs1800566 variant statuses affect the required warfarin maintenance dose.

中文翻译：

---

NQO1 多态性对华法林维持剂量的影响：系统评价和荟萃分析（rs1800566 和 rs10517）

本荟萃分析旨在分析NQO1多态性对华法林维持剂量的影响。我们使用严格的纳入和排除标准，在 PubMed、EMBASE 和 Cochrane 图书馆中搜索了 2021 年 7 月 7 日之前发表的符合条件的研究。提取了所需的数据，并在必要时咨询了专家。使用Review Manager 5.4版软件分析NQO1多态性与华法林维持剂量的关系。涉及 757 名患者的四篇文章被纳入荟萃分析。谁是患者NQO1 rs10517ģ载波（AG载体或GG载波）要求更高的48％的华法林的维持剂量比那些谁是AA载体。NQO1 rs1800566患者CT 携带者需要比 CC 携带者高 13% 的华法林剂量，与NQO1 rs1800566基因型的其他比较没有观察到关联。然而，通过比较NQO1 rs1800566 基因型获得的结果需要确认，因为在敏感性分析中发现了结果的显着变化。我们的荟萃分析表明NQO1 rs10517 和NQO1 rs1800566 变异状态影响所需的华法林维持剂量。